TrastuRel (Trastuzumab) is a humanized IgG1 kappa recombinant monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2), a transmembrane receptor protein coded by a proto-oncogene. TrastuRel contains human framework regions and the complementary determining regions of a murine antibody.

Molecular weight of TrastuRel is around 149kDa. TrastuRel is currently approved for breast cancer and metastatic gastric cancer.

TrastuRel is available as sterile 150mg and 440mg lyophilized powder in vials for intravenous administration.